The AI Revolution in Radiology: How One $269 Million Deal Is Reshaping Medical Imaging

RadNet, one of America's largest outpatient imaging providers, just made a massive bet on artificial intelligence in radiology—and it's not about detecting rare diseases. The company is acquiring Paris-based Gleamer for up to €230 million ($269.05 million) in an all-cash deal that will be integrated into RadNet's digital health subsidiary, DeepHealth. The combination creates the world's largest provider of clinical radiology AI solutions, covering MRI, CT, X-ray, mammography, and ultrasound imaging.

While much of the early hype around medical AI focused on finding obscure, rare conditions, the real economic engine of an imaging center is routine work. Plain film X-rays account for nearly 25% of RadNet's massive imaging volume—and that's where Gleamer excels.

What Makes This Acquisition Different?

Gleamer has built an impressive footprint with over 700 customer contracts across 44 countries by mastering the automation of routine imaging tasks. The company's cloud-based AI solutions automatically triage musculoskeletal, breast, lung, and neurologic abnormalities, but here's the game-changer: Gleamer specializes in automated draft reporting.

Instead of a radiologist staring at a blank screen to dictate a standard X-ray result, the AI pre-populates a highly accurate draft report. The radiologist shifts from being a data-entry clerk to a final reviewer, drastically increasing the volume of exams they can safely read in a single shift. "By building on our combined strengths, we are redefining how imaging is delivered, at scale, with intelligence and automation," noted Kees Wesdorp, President and Chief Executive Officer of DeepHealth.

The Numbers Behind the Deal

Gleamer is a financial powerhouse. The company boasts an annual recurring revenue (ARR) compound annual growth rate exceeding 90% from 2022 through 2025, and is on track to hit approximately $30 million ARR in 2026. The company already holds four FDA-cleared and six CE-marked devices supporting over 25 clinical indications, giving it credibility in a heavily regulated market.

What makes this acquisition particularly strategic is that RadNet operates hundreds of physical imaging centers. Pure-play software startups often struggle to prove real-world return on investment because they lack a captive clinical environment to deploy their code. RadNet, however, can immediately deploy Gleamer's automated reporting and triage capabilities across its own network, expecting to see measurable productivity gains and operational cost efficiencies by the third quarter of 2026.

How AI Is Transforming Radiologist Workflows

• Automated Triage: Gleamer's AI automatically identifies and prioritizes abnormalities in musculoskeletal, breast, lung, and neurologic imaging, ensuring urgent cases are flagged first.
• Draft Report Generation: Instead of radiologists dictating from scratch, the AI pre-populates accurate draft reports, allowing doctors to review and finalize rather than create from zero.
• Volume Scaling: By reducing data-entry burden, radiologists can safely read significantly more exams per shift without sacrificing accuracy or quality.
• Multi-Modality Support: The combined DeepHealth-Gleamer platform covers MRI, CT, X-ray, mammography, and ultrasound, providing comprehensive imaging automation across an entire radiology department.

Why This Matters Beyond Radiology

This acquisition signals a broader shift in how healthcare organizations view AI. Rather than chasing headline-grabbing breakthroughs in rare disease detection, the real value is in automating the bread-and-butter work that consumes radiologists' time and strains healthcare systems. With radiologist shortages and burnout at critical levels, tools that increase productivity without requiring additional hiring are increasingly attractive to hospital administrators and imaging centers.

The timing also reflects growing confidence in AI's ability to handle routine clinical tasks. Gleamer's four FDA clearances and six CE marks demonstrate that regulators are comfortable with AI-assisted reporting when the technology is properly validated and integrated into clinical workflows. This regulatory validation makes it easier for other healthcare organizations to adopt similar tools without lengthy approval processes.

RadNet's investment in DeepHealth and Gleamer positions the company to capture significant market share in what's becoming a critical competitive advantage: the ability to deliver faster, more efficient imaging services while maintaining quality and reducing costs. By Q3 2026, we should have real-world data on whether this $269 million bet pays off—and whether other imaging providers will follow suit.